{"schema_version":"secwatch.filing_event.v1","accession":"0001297184-24-000033","form_type":"8-K","ticker":"AMPH","cik":"0001297184","company_name":"Amphastar Pharmaceuticals, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.758198+00:00","generated_at":"2026-06-02T08:51:57.975274+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Amphastar Q1 2024 net revenue $171.8M, GAAP EPS $0.81, adjusted EPS $1.04","bullets":["Net revenues of $171.8M vs $140.0M in Q1 2023, up 23% YoY.","GAAP net income $43.2M ($0.81 dil EPS) vs $26.0M ($0.50) a year ago.","Adjusted non-GAAP net income $55.3M ($1.04 dil EPS) vs $32.1M ($0.62) YoY.","BAQSIMI revenue grew 22% over Eli Lilly's reported Q1 2023 revenue.","No forward guidance provided in the release."],"urls":{"canonical":"https://secwatch.observer/filing/0001297184-24-000033","json":"https://secwatch.observer/filing/0001297184-24-000033.json","markdown":"https://secwatch.observer/filing/0001297184-24-000033.md","text":"https://secwatch.observer/filing/0001297184-24-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1297184/000129718424000033/0001297184-24-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1297184/000129718424000033/amph-20240508x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T08:51:57.975274+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c75da9401fad3a1334d4060d00a218a9faf584b1","claim":"Amphastar Pharmaceuticals, Inc. reported the three months ended March 31, 2024 results: revenue $171.8 million, net income $43.2 million, EPS $0.81 per share.","evidence_excerpt":"Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2024. ​ First Quarter Highlights ​ ● Net revenues of $171.8 million for the first quarter ● GAAP net income of $43.2 million, or $0.81 per share, for the first quarter","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1297184/000129718424000033/0001297184-24-000033-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Revenue","value":"$171.8 million"},{"label":"Net income","value":"$43.2 million"},{"label":"EPS","value":"$0.81 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}